Regulus Therapeutics Inc. (NASDAQ:RGLS) went down by -13.33% from its latest closing price compared to the recent 1-year high of $1.54. The company’s stock price has collected -7.14% of loss in the last five trading sessions. Press Release reported on 01/05/21 that Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Is It Worth Investing in Regulus Therapeutics Inc. (NASDAQ :RGLS) Right Now?
Plus, the 36-month beta value for RGLS is at 2.31. Opinions of the stock are interesting as 0 analysts out of 3 who provided ratings for Regulus Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $0.75. RGLS currently public float of 36.65M and currently shorts hold a 2.95% ratio of that float. Today, the average trading volume of RGLS was 1.64M shares.
RGLS’s Market Performance
RGLS stocks went down by -7.14% for the week, with a monthly drop of -3.31% and a quarterly performance of 125.00%, while its annual performance rate touched -7.87%. The volatility ratio for the week stands at 12.78% while the volatility levels for the past 30 days are set at 12.60% for Regulus Therapeutics Inc.. The simple moving average for the period of the last 20 days is -7.80% for RGLS stocks with a simple moving average of 67.58% for the last 200 days.
Analysts’ Opinion of RGLS
Many brokerage firms have already submitted their reports for RGLS stocks, with B. Riley FBR Inc. repeating the rating for RGLS by listing it as a “Neutral.” The predicted price for RGLS in the upcoming period, according to B. Riley FBR Inc. is $1 based on the research report published on March 28th of the previous year 2018.
Leerink Partners, on the other hand, stated in their research note that they expect to see RGLS reach a price target of $2. The rating they have provided for RGLS stocks is “Outperform” according to the report published on January 05th, 2018.
Chardan Capital Markets gave a rating of “Buy” to RGLS, setting the target price at $2.50 in the report published on June 13th of the previous year.
RGLS Trading at 32.39% from the 50-Day Moving Average
After a stumble in the market that brought RGLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.03% of loss for the given period.
Volatility was left at 12.60%, however, over the last 30 days, the volatility rate increased by 12.78%, as shares surge +5.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +145.39% upper at present.
During the last 5 trading sessions, RGLS fell by -7.14%, which changed the moving average for the period of 200-days by +145.28% in comparison to the 20-day moving average, which settled at $1.2720. In addition, Regulus Therapeutics Inc. saw -13.33% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at RGLS starting from Sonsini Peter W., who purchase 4,398,602 shares at the price of $0.62 back on Dec 04. After this action, Sonsini Peter W. now owns 6,451,056 shares of Regulus Therapeutics Inc., valued at $2,735,930 using the latest closing price.
Walker Paul Edward, the 10% Owner of Regulus Therapeutics Inc., purchase 4,398,602 shares at $0.62 during a trade that took place back on Dec 04, which means that Walker Paul Edward is holding 6,451,056 shares at $2,735,930 based on the most recent closing price.
Stock Fundamentals for RGLS
Current profitability levels for the company are sitting at:
- -246.40 for the present operating margin
The net margin for Regulus Therapeutics Inc. stands at -272.13. The total capital return value is set at -73.09, while invested capital returns managed to touch -261.55. Equity return is now at value -150.70, with -57.50 for asset returns.
Based on Regulus Therapeutics Inc. (RGLS), the company’s capital structure generated 76.57 points at debt to equity in total, while total debt to capital is 43.36. Total debt to assets is 36.42, with long-term debt to equity ratio resting at 0.28. Finally, the long-term debt to capital ratio is 0.16.
When we switch over and look at the enterprise to sales, we see a ratio of -0.50, with the company’s debt to enterprise value settled at -4.47. The receivables turnover for the company is 11.71 and the total asset turnover is 0.20. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.69.